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Abstract: Alzheimer’s disease (AD) is the most common form of dementia in the elderly population,
but its underlying cause has not been fully elucidated. Recent studies have shown that microRNAs
(miRNAs) play important roles in regulating the expression levels of genes associated with AD
development. In this study, we analyzed miRNAs in plasma and cerebrospinal fluid (CSF) from
AD patients and cognitively normal (including amyloid positive) individuals. miR-1273g-3p was
identified as an AD-associated miRNA and found to be elevated in the CSF of early-stage AD patients.
The overexpression of miR-1273g-3p enhanced amyloid beta (Aβ) production by inducing oxidative
stress and mitochondrial impairments in AD model cell lines. A biotin-streptavidin pull-down
assay demonstrated that miR-1273g-3p primarily interacts with mitochondrial genes, and that their
expression is downregulated by miR-1273g-3p. In particular, the miR-1273g-3p-target gene TIMM13
showed reduced expression in brain tissues from human AD patients. These results suggest that miR1273g-3p expression in an early stage of AD notably contributes to Aβ production and mitochondrial
impairments. Thus, miR-1273g-3p might be a biomarker for early diagnosis of AD and a potential
therapeutic target to prevent AD progression.
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1. Introduction

This article is an open access article

Alzheimer’s disease (AD) is the most common type of dementia. It is pathologically
characterized by the accumulation of extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles in the brain. AD patients show memory loss and cognitive
and behavioral impairments caused by massive neurodegeneration mainly at the medial
temporal lobe, which contains the hippocampus and surrounding cortical regions [1,2]. Aβ
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peptides produced by the sequential proteolysis of amyloid precursor protein (APP) by
γ-secretase and β-site APP cleaving enzyme 1 (BACE1) have long been thought to be a key
factor that initiates neurodegeneration in AD prior to NFT formation [3,4]. However, the
mechanisms underlying Aβ production and deposition in sporadic AD patients are still
poorly understood.
Recently, mitochondrial dysfunction has gained attention in the context of Aβ production and neurodegeneration [5,6]. When mitochondrial activity is defective, insufficient
energy production and reactive oxygen species overload induce cellular stress and eventual cell death [7]. Studies showed that the expression of mitochondrial enzymes and the
oxygen consumption rate (OCR) were significantly decreased and that oxidative stress
molecules, such as 8-hydroxyguanosine and nitrotyrosine, were increased in early-stage
AD patients [8,9]. In the 3xTG-AD mouse model, mitochondrial respiration was markedly
reduced prior to the appearances of cognitive impairment, Aβ plaques, or NFTs [10]. Several other studies demonstrated that impairment of mitochondrial function could induce
Aβ production and neurodegeneration. In particular, cybrid cells containing mitochondria
obtained from AD patients showed decreased mitochondrial activity and increased production of Aβ [11–13]. In addition, mitochondrial dysfunction by inhibitors of oxidative
phosphorylation complexes facilitated Aβ production [14,15], and oxidative stress induced
the expression of BACE1 [16–18]. Accordingly, studies focusing on the mechanism(s)
underlying mitochondrial dysfunction in AD will surely help us unravel the cause of
AD pathogenesis.
MicroRNAs (miRNAs), small non-coding RNAs, are known as an important regulator
of gene expression in various physiological processes [19]. Many miRNAs are associated
with Aβ processing or NFT formation, and their expression levels are shown to be differentially regulated in AD [20,21]. miRNAs stably exist in body fluids, either in their free form
or packaged into vesicles [22–24]. Monitoring miRNAs in cerebrospinal fluid (CSF), which
is in direct contact with brain tissue, is considered to be a promising strategy for detecting
early events of brain diseases [25,26]. Studies on the levels of miRNAs in blood or CSF from
early-stage AD patients revealed that the plasma levels of miR-92a-3p, miR-181c-5p, and
miR-210-3p were upregulated in mild cognitive impairment (MCI) and AD patients [27].
Another study analyzed changes in the level of miRNAs in CSF according to various Braak
stages or plaque density stages to determine AD-associated miRNAs [28]. A meta-analysis
of miRNAs in brain, blood, and CSF identified miRNAs that appeared to be consistently
associated with AD progression [29]. However, we know relatively little about miRNAs in
early-stage AD patients and how the altered miRNAs might function in AD progression.
In this study, we report that miR-1273g-3p is significantly upregulated in CSF of earlystage AD patients, as assessed by microarray and qPCR analyses. A pull-down experiment
performed using biotinylated-miR-1273g-3p revealed that miR-1273g-3p primarily interacts
with mitochondrial genes and downregulates their expression levels. Here, miR-1273g-3p
causes mitochondrial dysfunction and subsequent aspects of AD pathogenesis, such as
neurodegeneration and the formation of Aβ plaques.
2. Materials and Methods
2.1. Human Plasma and CSF Samples
Human plasma and CSF samples from 195 participants aged 65–90 years were obtained from the National Research Center for Dementia at Chosun University in Gwangju,
Korea. All participants were tested for a full dementia screening, including medical history,
neurological examination, laboratory and neuropsychological tests, and brain MRI. The
clinical diagnosis was made according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer Disease and Research Disorders
Association [30]. Participants in cohort 1 for microarray of plasma miRNAs consisted
of amnestic MCI (aMCI), AD patients and cognitively normal controls. Participants for
qPCR analysis of miRNAs in plasma (cohort 2) and CSF (cohort 3) additionally underwent brain amyloid-PET imaging using 18 F-florbetaben and CSF analysis of Aβ40/42
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and pTau181 /Tau within 1 year from the screening test. The clinical and demographic
information of participants for this study is presented in Table 1.
Table 1. Clinical and demographic data of participants.
Cohort

Diagnosis

n (M/F)

Age, y

p-Value

K-MMSE

p-Value

Amyloid
PET

Microarray for
miRNAs in plasma
(Cohort 1)

Control
aMCI
AD

36 (16/20)
24 (12/12)
36 (20/16)

72.86 ± 4.72
74.22 ± 4.51
73.58 ± 5.72

0.115
0.344

27.31 ± 2.69
25.94 ± 2.54
17.34 ± 8.17

0.018
2.35 × 10−9

-

qPCR for
miRNAs in plasma
(Cohort 2)

Control
PSAD
PDAD
AD

31 (18/13)
12 (6/6)
20 (10/10)
20 (8/12)

72.85 ± 5.31
73.99 ± 3.32
74.38 ± 4.80
72.54 ± 3.61

0.247
0.150
0.411

27.10 ± 1.83
26.67 ± 3.55
25.35 ± 3.69
17.50 ± 4.83

0.28
1.45 × 10−2
8.67 × 10−14

negative
positive
positive
positive

qPCR for
miRNAs in CSF
(Cohort 3)

Control
PSAD
PDAD
AD

13 (7/6)
10 (5/5)
13 (7/6)
14 (7/7)

74.46 ± 4.66
73.75 ± 4.24
74.08 ± 5.87
70.39 ± 4.82

0.373
0.428
0.017

26.62 ± 1.56
26.90 ± 3.28
25.46 ± 4.03
17.93 ± 4.91

0.393
0.173
1.13 × 10−6

negative
positive
positive
positive

Plasma samples were prepared twice by centrifugation (3000 rpm, 4 ◦ C, 10 min) of
fasting blood samples in EDTA vacutainer within 20 min after collection and immediately
stored at −80 ◦ C until use. CSF samples were collected in Falcon polypropylene tubes
(BD Biosciences, Franklin Lakes, NJ, USA), centrifuged for 10 min at 2000 rpm at 4 ◦ C and
immediately stored at −196 ◦ C liquid nitrogen until use.
2.2. Human Postmortem Brain Samples
Formalin-fixed paraffin embedded brain samples were obtained from the Victorian
Brain Bank Network (Victoria, Australia) and Chonnam National University Hwasun
Hospital and Medical School (Jeollanam-do, Korea). The samples used in our experiment
were derived from 8 AD patients (64–88 years, 6 males and 2 females) and 5 cognitively
normal controls (64–79 years, 4 males and 1 female).
2.3. Cell Culture
H4 cell line expressing APPswemut (H4-APPswe) were gifted from Dr. Jung-Hyuck
Ahan in Ewha Womans University School of Medicine, Seoul, Korea. H4-APPswe cells
were maintained in Dulbecco modified Eagle’s medium (DMEM, Gibco, Amarillo, TX,
USA) with 10% fatal bovine serum (Hyclone, Logan, UT, USA), 1X Antibiotic-Antimycotic
(Gibco) and 500 ug/mL geneticin (Gibco). SH-SY5Y cell line (ATCC) were maintained in
DMEM supplemented with 10% FBS, 1x Antibiotic-Antimycotic. All cell lines were cultured
in a humidified incubator containing 95% air/5% CO2 at 37 ◦ C and routinely tested for
mycoplasma using MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland). For
transfection, about 25,000/cm2 H4-APPswe cells or 40,000/cm2 SH-SY5Y cells were plated
on 6-well plate or cover glasses in 12-well plate, and transfected next day. For transfection,
about 25,000/cm2 H4-APPswe cells or 40,000/cm2 SH-SY5Y cells were plated on 6-well
plate or cover glasses in 12-well plate, and transfected next day.
2.4. Plasmids, miRNA Mimic and Inhibitor and Transfection
An amount of 75 nM (unless otherwise stated) miR-1273g-3p mimic and mimic negative control (Dharmacon, Lafayette, CO, USA); 10 nM miRCURY LNA miR-1273g-3p power
inhibitor and inhibitor control (Qiagen, Hilden, Germany); and 50 nM ON-TARGETplus
siRNAs targeting TIMM13 and non-targeting control siRNA (Dharmacon) were transfected
into cells using DharmaFECT 1 reagent (Dharmacon). The 30 UTR of GLRX5, MTCH1,
VDAC2 and TIMM13 and coding sequence of TIMM13 were amplified by PCR using
cDNA of SH-SY5Y cells as template and inserted into pEGFP C1 and pcDNA 3.0 vector,
respectively, using EZ-cloning kit (Enzynomics, Daejeon, Korea). The primers are described
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in Table S4. Plasmids were transfected into cells using Lipofectamine 3000 (Invitrogen,
Waltham, MA, USA).
2.5. Microarray
Each 1ml of plasma from 4 participants was used for microarray. Total RNA was
isolated using miRNeasy serum/plasma kit (Qiagen) following the manufacturer’s instructions and concentrated by ethanol precipitation method. After a quality check using
Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA), 1 µg total RNA was labeled using the
FlashTagTM Biotin HSR RNA Labeling kit (Affymetrix, Santa Clara, CA, USA), hybridized
to Affymetrix GeneChip miRNA array 4.0. and scanned with an Affymetrix GCS 3000 scanner (Affymetrix). For data extraction, Affymetrix GeneChip Command Console Software
was used. Data were normalized by Robust Multi-array Average and detection above
background methods using Expression Console 1.4.
2.6. Quantitative Real-Time PCR (qPCR)
Total RNA from 50 µL plasma and 200 µL CSF was isolated using miRNeasy
serum/plasma kit (Qiagen), and total RNA from cells was isolated using miRNeasy
micro kit (Qiagen) according to the manufacturer’s instruction. The cDNAs of miRNA
and mRNA were synthesized using miScript RT II kit (Qiagen) and the PrimeScript™ RT
Master Mix (Takara, Shiga, Japan), respectively. qPCR was conducted using miScript SYBR
Green PCR Kit (Qiagen) for miRNAs and TB Green® Premix Ex Taq™ (Takara) for mRNAs
in LightCycler480 system (Roche, Basel, Switzerland). Primers for miRNAs were purchased
from Qiagen. Primers for quantification of mRNAs are described in Table S4. The level
of miRNAs in plasma and CSF samples was calculated using ∆Ct method with reference
miRNAs which were selected by referring to recommendation in Biofluids guidelines
by Exiqon (Vedbaek, Denmark). The relative level of miRNAs and mRNAs in cells was
calculated using ∆∆Ct method with reference to the control group normalized by RNU6
for miRNAs and GAPDH for mRNAs.
2.7. Biotinylated-miRNA Pull-Down Assay
Biotinylated-miRNA pull-down assay was performed as described previously [31].
Briefly, H4-APPswe cells were transfected with 75 nM biotinylated-miR-1273g-3p or biotinylated cel-miR-39-3p as a negative control (Exiqon). After 24 h, cells were lysed with
hypotonic buffer containing 10 mM KCl, 1.5 mM MgCl2 , 10 mM Tris-HCl (pH 7.5), 5 mM
dithiothreitol, 0.5% NP40, 50 U/mL SUPERaseIn (Invitrogen) and 1x protease inhibitor
cocktail (Roche). The supernatants were transferred to 25 µL of streptavidin-containing
myOne C1 Dynabeads (Invitrogen) which were pre-blocked with 1 µg/µL BSA and MS2
RNA (Roche), and the same volume of 2 M NaCl hypotonic buffer as the lysate was added.
The mixture was incubated for 30 min with gentle rotation and the beads were washed
with 1 M NaCl hypotonic buffer. Total RNA was extracted using miRNeasy micro kit
(Qiagen) according to the manufacturer’s instruction.
2.8. RNA Sequencing (RNAseq) and Gene Ontology (GO) Analysis
A library of mRNAs was constructed using TruSeq Stranded Total RNA H/M/R Prep
Kit (Illumina, San Diego, CA, USA) and the quality of library DNA was confirmed using
2200 TapeStation (Agilent). RNAseq was conducted using HiSeq 2500 system (Illumina).
Sequence reads were mapped with human reference genome (hg19) using Tophat v2.0.13
with 79.64% of mapping rates and abundance of mRNAs represented by fragment per
kilobase of transcript per million was estimated using Cuffdiff v. 2.2.0. GO was analyzed
using DAVID Bioinformatics Resources v6.8 (https://david.abcc.ncifcrf.gov/, accessed on
5 January 2018 through 22 September 2021).
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2.9. Bioinformatics Analysis
We analyzed the expression of GLRX5, MTCH1 and TIMM13 in the human prefrontal
cortex by using RNAseq data for AaD patients (GN accession: GN368) and normal participants (GN accession: GN367) from the Harvard Brain Tissue Resource Center [32] provided
in the publicly available GeneNetwork database (http://www.genenetwork.org/, accessed
on 29 April 2021).
2.10. Measurements of Oxygen Consumption Rate (OCR)
After 24 h of transfection, cells were seeded on XFp Miniplate (Agilent) at a density of
20,000 cells/80 µL for H4-APPswe and 40,000 cells/80 µL for SH-SY5Y. After 24 h, media
was changed to 180 µL of Seahorse XF DMEM (Agilent) supplemented with 10 mM glucose
(Agilent), 1 mM sodium pyruvate (Agilent) and 1x Glutamax (Gibco). OCR was analyzed
using Seahorse XFp analyzer (Agilent) with sequential addition of 1.5 µM Oligomycin,
carbonyl cyaide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 2 µM for H4-APPswe and
0.5 µM for SH-SY5Y) and 0.5 µM rotenone/antimycin A in Seahorse XFp Cell Mito Stress
Test Kit (Agilent). The data were analyzed using WAVE software (Agilent) and normalized
by cell viability.
2.11. Fluorescence Immunohistochemistry
Paraffin-sections were rehydrated and boiled in epitope retrieval solution (IHC World,
Woodstock, MD, USA), followed by incubation with antibodies against TIMM13 (Novus,
USA; NBP2-13431). Antigen-antibody complexes were visualized using the Alexa Fluor
conjugated secondary antibody (Invitrogen). Aβ plaques were stained with 0.01 mg/mL
Methoxy-X04 for 30 min. Fluorescence images were obtained using a Fluoview FV 1000 confocal microscope (Olympus, Japan) with FV10-MSASW software and analyzed using
MetaMorph software (Molecular Devices, San Jose, CA, USA).
2.12. Neurite Outgrowth Analysis
SH-SY5Y cells were differentiated with retinoid acid and brain-derived neurotrophic
factor as previously reported [33]. Differentiated cells were transfected with miR-1273g-3p
mimic and negative control at day 14 and immunostained using anti-MAP2 antibody
(Sigma, St. Louis, MO, USA). Fluorescence images were obtained using a Fluoview FV
1000 confocal microscope (Olympus, Japan) with FV10-MSASW software and analyzed
using MetaMorph software (Molecular Devices, San Jose, CA, USA).
2.13. Statistical Analysis
Differences between two groups were assessed using Student’s t-test. To evaluate
sensitivity and specificity of miR-1273g-3p for classification of each stage of AD group
from control group, receiver operating characteristic (ROC) curve and the area under curve
(AUC) were calculated. Correlation analysis between two groups was performed using
Pearson’s correlation. Variability in all plots and graphs is presented as the ± SEM. All
p < 0.05 were considered to be significant.
3. Results
3.1. miR-1273g-3p Is Elevated in the Plasma and CSF of AD Patients
To identify AD-associated miRNAs, we obtained plasma samples from 24 aMCI
patients (pooled into 6 samples), 36 AD patients (pooled into 9 samples) and 36 agematched cognitively normal individuals (controls, pooled into 9 samples) and screened
miRNAs in these samples using a GeneChipTM miRNA 4.0 array. The participants were
at least 65 years of age who had been clinically diagnosed with AD but had not been
subjected to verification of this diagnosis by amyloid-PET imaging or CSF test (Cohort 1 in
Table 1). Microarray analysis of plasma samples allowed us to identify 10 miRNAs that
were differentially expressed in aMCI patients versus controls and 5 miRNAs that were
differentially expressed in AD patients versus controls. Among them, we focused on miR-
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verification of this diagnosis by amyloid-PET imaging or CSF test (Cohort 1 in Table 1).
Microarray analysis of plasma samples allowed us to identify 10 miRNAs that were differentially expressed in aMCI patients versus controls and 5 miRNAs that were differentially expressed in AD patients versus controls. Among them, we focused on miR-1273g3p that dramatically increased in plasma of both aMCI and AD patients (Figure61A,
of 21Table
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Figure 1. Analysis of miRNAs in plasma and CSF from four groups of AD. (A) Alzheimer’s disease (AD)-associated

Figure 1. Analysis of miRNAs in plasma and CSF from four groups of AD. (A) Alzheimer’s disease (AD)-associated miRmiRNAs selected by microarray analysis of miRNAs in plasma from 24 amnestic mild cognitive impairment (aMCI) patients,
NAs selected by microarray analysis of miRNAs in plasma from 24 amnestic mild cognitive impairment (aMCI) patients,
36 AD patients, and 36 controls (absolute fold change > 1.5; p < 0.05, Student’s t-test). Bar graphs show fold change of
36 AD patients, and 36 controls (absolute fold change > 1.5; p < 0.05, Student’s t-test). Bar graphs show fold change of
miRNAs in aMCI (left) and AD (right) relative to the control. Orange and blue bars present up- and downregulated miRNAs,
miRNAs in aMCI (left) and AD (right) relative to the control. Orange and blue bars present up- and downregulated miRare presented as mean ± SEM. (B) Quantification of miR-1273g-3p in plasma from the presymptomatic
NAs, respectively.
respectively.Data
Data
are presented as mean ± SEM. (B) Quantification of miR-1273g-3p in plasma from the presymptoAD (PSAD, n = 12), prodromal AD (PDAD, n = 20), AD (n = 20), and control (n = 31) groups, as assessed by qPCR. Column
matic AD (PSAD, n = 12), prodromal AD (PDAD, n = 20), AD (n = 20), and control (n = 31) groups, as assessed by qPCR.
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The upper and lower limits of the box plot indicate the 75th and 25th percentiles, and the line in each box indicates the
mean of each group. C, control.

Cells 2021, 10, 2697

7 of 21

To further substantiate the association of miR-1273g-3p with AD, we examined the
levels of miR-1273g-3p in CSF of PSAD (n = 10), PDAD (n = 13), AD (n = 14), and control
(n = 13) individuals using qPCR (Cohort 3 in Table 1). CSF samples were obtained from
the same participants whose samples were used for qPCR analysis of plasma miRNAs,
and were further obtained for seven new participants, including two controls and one
PSAD, one PDAD, and three AD patients. Compared to controls, significant increase in the
CSF level of miR-1273g-3p was detected in PSAD, PDAD, and AD patients (Figure 1C). In
addition, the level of miR-1273g-3p in CSF was relatively higher than the levels of other
miRNAs, such as AD-related miR-29a-3p [20], miR-16-5p and miR-451a, which are highly
abundant in blood [34] (Table S3). The ROC curve generated using CSF-derived qPCR
data indicated that the level of miR-1273g-3p could be used to clearly distinguish PSAD,
PDAD and AD patients from age-matched controls (AUC > 0.75) (Figure 1D). Moreover,
the level of CSF miR-1273g-3p was negatively correlated with the level of CSF Aβ42, which
is known to decrease with AD progression [35] (Figure 1E). Based on these data, we suggest
that miR-1273g-3p is an AD-associated miRNA.
Data are presented as mean ± standard deviation. K-MMSE, Korean mini-mental state
exam; aMCI, amnestic mild cognitive impairment; PSAD, presymptomatic Alzheimer’s
disease; PDAD, prodromal Alzheimer’s disease; AD, Alzheimer’s disease.
3.2. miR-1273g-3p Facilitates Aβ Production in an AD Model Cell Line
To investigate the association of miR-1273g-3p with AD progression, we examined
changes in Aβ production and hyper-phosphorylation of tau in neuroglioma H4 cells
expressing APPswemut ; H4-APPswe), an AD model cell line. We overexpressed miR1273g-3p by transfecting cells with a synthetic miR-1273g-3p mimic (Figure 2A). First, we
quantified the concentration of Aβ42 and Aβ40 in conditioned medium of H4-APPswe
cells by ELISA. Both Aβ42 and Aβ40 were considerably increased in conditioned medium
of miR-1273g-3p-overexpressing cells compared to the negative control (Figure 2B). The
increase in Aβ in conditioned medium of miR-1273g-3p overexpressing H4-APPswe was
validated by Western blotting (Figure S1A). In addition, the level of APP protein was
significantly higher, whereas the levels of c-terminal fragments (CTFs) were not changed,
in miR-1273g-3p overexpressing H4-APPswe cells compared with negative control cells
(Figure S1A).
Based on these observations, we tested the expression of APP-processing genes,
such as BACE1, presenilin 1 (PS1), nicastrin and a disintegrin and metalloproteinase 10
(ADAM10). Western blot analysis demonstrated that the protein levels of BACE1 and
nicastrin were significantly increased by miR-1273g-3p overexpression in H4-APPswe cells,
whereas the levels of PS1 and ADAM10 were unchanged (Figure 2C). The mRNA levels
of BACE1 and nicastrin were also increased, indicating that the expressions of BACE1
and nicastrin are transcriptionally regulated by miR-1273g-3p (Figure 2D). miR-1273g-3passociated increases in BACE1 and Aβ42 production were observed even at lower levels of
miR-1273g-3p overexpression which mimics the two-fold increases observed in the CSF
of AD patients (Figure S1B–D). The expression levels of p-TauT231 and p-TauS396 were not
altered by miR-1273g-3p overexpression in H4-APPswe cells (Figure 2E). Taken together,
these results suggest that the increase of miR-1273g-3p expression induces Aβ production
in H4-APPswe cells.
3.3. The miR-1273g-3p-Mediated Upregulation of BACE1 Is Caused by Oxidative Stress
As BACE1 is the rate-limiting enzyme for production of Aβ peptides [36], we first
investigated the factors that regulate BACE1 expression. BACE1 expression is well known
to be regulated by stress-induced molecules, such as hypoxia induced factor 1α (HIF1α)
and c-Jun N-terminal kinase (JNK) [16,18,37]. Thus, to elucidate the mechanism by which
miR-1273g-3p upregulates BACE1 and downstream Aβ production, we examined the
ability of miR-1273g-3p overexpression to alter one of the stress-induced molecule, JNK.
The overexpression of miR-1273g-3p in H4-APPswe cells dramatically increased the level
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Figure 2. miR-1273g-3p increases Aβ production in H4-APPswe cells. (A) The level of miR-1273g-3p measured by qPCR in
H4-APPswe cells transfected with miR-1273g-3p mimic relative to negative control cells. Data were normalized by RNU6
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Figure 3. miR-1273g-3p induces oxidative stress to mediate the upregulation of BACE1 in H4-APPswe cells. (A) Western
blotting for BACE1, p-JNKT183/Y185 , and JNK in H4-APPswe cells transfected with miR-1273g-3p mimic or negative control.
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MitoTrackerTM Red CMX Ros, the cells overexpressing miR-1273g-3p showed significantly
lower staining intensity compared to negative control cells (Figure 4A,B), suggesting that
mitochondrial membrane potential was defected in the former. This result was verified by
staining with the carbocyanine-based reagent MitoTrackerTM Deep Red FM (Figure S3A).
In addition, miR-1273g-3p-overexpressing cells demonstrated dramatic morphological
changes of mitochondria. The numbers of cells with fragmented mitochondria were increased and the numbers of tubulated mitochondria decreased (Figure 4C). These findings
supported the qPCR results showing that the levels of expression of MFN1/2 and OPA1,
which participate in mitochondrial fusion [38], were decreased, whereas the level of expression of FIS1, which facilitates mitochondrial fission [39], was increased in miR-1273g-3p
overexpressing H4-APPswe cells (Figure S3B). The increased concentration of cellular hydrogen peroxide (H2 O2 ) and the intensity of CellROXTM Deep Red staining, which detects
intracellular ROS, in miR-1273g-3p overexpressing H4-APPswe cells indicate that these
cells are under oxidative stress (Figure 4D and Figure S3C). When we measured the levels
of mRNAs encoding NRF2, SOD1/2 and ACO2, which are responsible for anti-oxidative
stress, we found that miR-1273g-3p overexpression significantly decreased the levels of
SOD1/2 (Figure S3D).
In analysis of the real-time OCR, basal and ATP-linked OCR were considerably decreased in miR-1273g-3p-transfected H4-APPswe cells. The maximum OCR, which was
measured using the uncoupling reagent, FCCP, was also significantly reduced by miR1273g-3p (Figure 4E). The glycolysis rate, as determined by measuring the extracellular
acidification rate (ECAR) while measuring OCR, was also significantly decreased in miR1273g-3p-overexpressing H4-APPswe cells (Figure S3E), indicating that these cells were
energy deprived. In miR-1273g-3p mimic-transfected H4-APPswe cells, the anti-apoptotic
gene, Bcl-2, was decreased; the pro-apoptotic genes, Bax and Bak, were significantly
increased (Figure 4F); and cell viability was reduced (Figure 4G).
To elucidate the function of miR-1273g-3p in neuronal cells, we analyzed the changes
of mitochondrial function and BACE1 expression using neuroblastoma cell line SH-SY5Y.
In miR-1273g-3p-overexpressing SH-SY5Y cells stained with MitoTrackerTM Red CMX Ros,
the fluorescence intensity was decreased, the number of cells with fragmented mitochondria
was considerably increased, and the number of cells with tubulated mitochondria was
decreased (Figure 4H–J), reflecting a loss of mitochondrial membrane potential. The basal
and maximal OCR were decreased (Figure 4K) and ECAR was slightly, but not significantly,
decreased (Figure S3F) in miR-1273g-3p-overexpressing SH-SY5Y cells, indicating that ATP
production and the mitochondrial respiration capacity were reduced in these cells. This
was associated with an inhibition of neurite outgrowth (Figure 4L) and increased BACE1
expression (Figure 4M). Taken together, our results indicate that miR-1273g-3p is likely to
induce mitochondrial dysfunction, and therefore an abnormal increase of miR-1273g-3p
would disrupt mitochondrial functions leading to energy deprivation, oxidative stress, and
eventual cell degeneration.
3.5. miR-1273g-3p Interacts with and Downregulates the Expression Levels of Mitochondrial
Genes in H4-APPswe Cells
To identify the target genes of miR-1273g-3p, we pulled down mRNAs with biotinylatedmiR-1273g-3p (biot-miR-1273g-3p) in H4-APPswe cells and profiled the mRNAs by highthroughput RNAseq (Figure 5A). After pull-down of biot-miR-1273g-3p, we analyzed the
level of miR-1273g-3p and the reference miRNAs, miR-191-5p and miR-16-5p, in the pulldown samples and supernatants by qPCR to confirm the efficiency and specificity of the
experiment (Figure S4A). RNAseq analysis of the pull-down samples identified 1539 genes
whose mRNAs interacted with biot-miR-1273g-3p (Figure 5B). GO analysis predicted
‘mitochondrion’ as the most enriched GO term, with 192 genes falling into this category
(Figure 5C). From among them, we used the p-values to select four mitochondrial genes
for further analysis: GLRX5 (glutaredoxin 5), MTCH1 (mitochondrial carrier 1), VDAC2
(voltage dependent anion channel 2) and TIMM13 (translocase of inner mitochondrial
membrane 13). We verified their binding with miR-1273g-3p by qPCR analysis (Figure 5D).
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Figure 4. miR-1273g-3p impairs mitochondrial function in H4-APPswe and SH-SY5Y cells. (A–C) Representative images
of MitoTracker Red CMX Ros (MitoTracker Red) staining for H4-APPswe cells transfected with miR-1273g-3p mimic or
negative control. Magnified views of the boxed area are presented in the second row. Scale bar: first row, 20 µm; second row,
10 µm (A). Intensity of MitoTracker Red is shown in (B) (n = 3, 26-65 cells were analyzed per experiment) and analysis of
mitochondrial morphological changes is shown in (C) (n = 3, 43-135 cells per experiment). (D–G) Relative concentration of
H2 O2 (D) (n = 3), oxygen consumption rate (OCR) analysis (E) (n = 4), quantification of Bcl-2, Bax, and Bak mRNAs by qPCR
(F) (n = 4), and percentage of cell viability assessed by WST-1 (G) (n = 3) in H4-APPswe cells transfected with miR-1273g-3p
mimic or negative control. (H–J) Representative images of MitoTracker Red staining for SH-SY5Y cells transfected with
miR-1273g-3p mimic or negative control. Magnified views of the boxed area are presented in the second row. Scale bar: first
row, 20 µm; second row, 10 µm (H). Intensity of MitoTracker Red is shown in (I) (n = 3, 42-137 cells per experiment) and
analysis of mitochondrial morphological changes is shown in (J) (n = 3, 57-131 cells per experiment). (K–M) Measurements
of OCR (K) (n = 4), neurite outgrowth analysis by immunostaining of MAP2 (L) (n = 3; Scale bar: 100 µm), and Western
blotting for BACE1 (M) (n = 3) in SH-SY5Y cells transfected with miR-1273g-3p mimic or negative control. Mitochondrial
morphology was defined as fragmented, mainly round shape; tubulated, mainly long shape; and intermediate, mixture
of round and tubulated shape. Real-time OCR data are presented as a percentage relative to the first negative control
measurement; bar graph indicates the percentage of OCR relative to the basal value of the negative control. All data are
presented as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; n.s., non-significant (Student’s t-test). NC, mimic negative
control; 1273, miR-1273g-3p mimic.
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chondrial genes for further analysis: GLRX5 (glutaredoxin 5), MTCH1 (mitochondrial carrier 1), VDAC2 (voltage dependent anion channel 2) and TIMM13 (translocase of inner
mitochondrial membrane 13). We verified their binding with miR-1273g-3p by qPCR analysis (Figure 5D).
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Figure 5. Identification of target genes for miR-1273g-3p. (A) Experimental scheme of pull-down assays performed using
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To confirm that miR-1273g-3p modulates the expression levels of these target genes
by binding directly to their 30 UTRs, we constructed reporter vectors in which the 30 UTR
sequences of GLRX5, MTCH1, VDAC2, and TIMM13 were inserted after the stop codon of
the GFP gene. TargetScan showed that the sequences of the 30 UTRs of MTCH1 and VDAC2
completely match the seed sequence of miR-1273g-3p, whereas GLRX5 and TIMM13 have
one and three putative sequences, respectively, with partially matched bases. Each putative
target sequence was replaced with mismatched bases in mutant constructs (Figure 5E).
These reporter plasmids were co-transfected with miR-1273g-3p mimic or negative control
into H4-APPswe cells. The expression of GFP by the reporter vectors containing the WT
30 UTR sequences of GLRX5, MTCH1 and TIMM13 were markedly downregulated in the
presence of miR-1273g-3p, whereas the expression of GFP by reporter vector containing the
WT 30 UTR of VDAC2 was not (Figures 5F and S4B). The miR-1273g-3p-mediated downregulation of GFP was completely abrogated by a mutation in the 30 UTR of MTCH1 and by a
triple mutation in the 30 UTR of TIMM13, and was partially abrogated by a mutation in the
30 UTR of GLRX5 and by single mutations in the 30 UTR of TIMM13 (Figures 5F and S4B).
When miR-1273g-3p was overexpressed in H4-APPswe and SH-SY5Y cells, the protein
expression levels of TIMM13, GLRX5, and MTCH1 were reduced whereas that of VDAC2
remained unchanged (Figure 5G,H). Cell staining further confirmed the reduction of
TIMM13 and GLRX5 expression by miR-1273g-3p in H4-APPswe (Figure S4C). Transfection
of various concentrations of miR-1273g-3p mimic into H4-APPswe cells dose-dependently
downregulated TIMM13, GLRX5, and MTCH1 expression and increased JNK activation
(Figure S4D). These data support that miR-1273g-3p interacts with and negatively regulates
various mitochondrial genes in both H4-APPswe and SH-SY5Y cells.
3.6. Modulation of the Expression of miR-1273g-3p Target Genes Affects Mitochondrial Function
and Aβ42 Production
To further investigate the function of TIMM13, which was significantly downregulated
in miR-1273g-3p-transfected H4-APPswe and SH-SY5Y cells, we used siRNA to knock
down TIMM13 in H4-APPswe cells. We found that TIMM13 knockdown moderately
increased the levels of BACE1, p-JNK, and Aβ42 (Figure 6A,B), but reduced the maximum
OCR (Figure 6C). Based on these data, we sought to overexpress TIMM13 in miR-1273g3p-overexpressing H4-APPswe cells, in which TIMM13 expression was downregulated.
Indeed, we found that the overexpression of TIMM13 moderately restored BACE1 and
Aβ42 production to the basal level in miR-1273g-3p-overexpressing H4-APPswe cells
(Figure 6D,E). The activation of JNK signaling by miR-1273g-3p was also relieved by the
overexpression of TIMM13 (Figure 6D). As we had found that treatment with an miR-1273g3p inhibitor alleviated the increase of Aβ42 production in miR-1273g-3p-overexpressing
H4-APPswe (see Figure 3F,G), we investigated whether the expression of target genes could
be rescued by co-transfecting the miR-1273g-3p mimic and inhibitor into H4-APPswe cells.
Western blot analyses revealed that the expression of GLRX5, MTCH1 and TIMM13, which
were decreased by miR-1273g-3p overexpression, was recovered by miR-1273g-3p inhibitor
in H4-APPswe cells (Figure 6F). The maximum and ATP-linked OCR were also restored
to the level seen in the negative control by co-transfection of the miR-1273g-3p inhibitor
in H4-APPswe cells (Figure 6G). Taken together, these data suggest that miR-1273g-3p
regulates the expression levels of genes associated with mitochondrial function and in turn
induces Aβ42 production.
3.7. TIMM13 Is Downregulated in Hippocampi of Human AD Patients
We analyzed the expression levels of three miR-1273g-3p target genes, GLRX5, MTCH1,
and TIMM13, in brain tissues from AD patients using the GN367 and GN368 datasets of
GeneNetwork (http://www.genenetwork.org/, accessed 29 April 2021). The expression
levels of three genes were significantly decreased in AD patients compared to controls
(Figure 7A). To confirm these findings, we analyzed TIMM13 expression by fluorescence
immunohistochemistry in human hippocampus tissues obtained from 8 AD patients and
5 controls. TIMM13 was abundantly expressed in normal brain, but was only faintly
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3.7. TIMM13 Is Downregulated in Hippocampi of Human AD Patients
We analyzed the expression levels of three miR-1273g-3p target genes, GLRX5,
MTCH1, and TIMM13, in brain tissues from AD patients using the GN367 and GN368
datasets of GeneNetwork (http://www.genenetwork.org/, accessed 29 April 2021). The expression levels of three genes were significantly decreased in AD patients compared to
controls (Figure 7A). To confirm these findings, we analyzed TIMM13 expression by fluorescence immunohistochemistry in human hippocampus tissues obtained from 8 AD patients and 5 controls. TIMM13 was abundantly expressed in normal brain, but was only
faintly detected in the stratum pyramidal layers CA1, CA2 and CA3 of the hippocampus
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in AD brains (Figure 7B). Collectively, these data suggest that TIMM13 downregulation
15 of 21
in AD brains is correlated with the pathogenesis of AD.
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each group; and whiskers indicate outliers. Scale bar: 50 μm. ***p < 0.001; n.s., non-significant (Student’s t-test).
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4. Discussion
Most AD patients have sporadic AD, consisting of late onset AD that begins after
age 65 years, rather than familial AD. As the cause of sporadic AD has not yet been
fully elucidated, it remains difficult to predict AD onset at early stage. This is a problem,
because early diagnosis and treatment can delay AD progression [40]. Many studies
have suggested that genetic mutations, such as those in APOE or TREM2, are closely
associated with sporadic AD [41]. Epigenetic factors, such as DNA methylation, histone
modification and non-coding RNAs, have been also suggested as risk factors of sporadic
AD [42]. Owing to their essential role in fine-tuning gene expression, non-coding RNAs,
particularly miRNAs, may be biomarkers of sporadic AD or even targets for treatment.
miR-29a/b-1 clusters and miR-132-3p, which regulate the expression of genes involved
in APP processing and tau phosphorylation, were shown to be differentially expressed in
postmortem brains of AD patients [20,21]. To determine early miRNA markers, several
studies profiled miRNAs in CSF or plasma from mild late onset AD or MCI patients [27,43].
However, miRNAs are not yet considered to be reliable biomarkers for AD diagnosis
because they have not yet been sufficiently analyzed in the early stage of AD, nor have
functional analyses been performed in this context. Using high-throughput analysis, the
present study found that miR-1273g-3p is a novel AD-associated miRNA present in the
plasma and CSF of individuals with PSAD who were presumed to be in the early stages of
AD. We then elucidated its cellular function in AD progression.
We found that miR-1273g-3p was constantly elevated in CSF of PSAD, PDAD, and
AD patients compared to controls, and also showed significantly higher levels in plasma
of AD patients (Figure 1). This finding is supported by a study showing that the level of
mir-1273g, a precursor of miR-1273g-3p, is one of miRNAs increased in blood from AD
patients [44]. To our knowledge, however, no study has investigated the role of miR-1273g3p in AD pathogenesis. In addition, our results are considered reliable due to the use of
accurate AD diagnosis through amyloid-PET imaging and assessment of AD risk factors,
and reproducibility across the three cohorts. We suggest that CSF miR-1273g-3p could be a
good biomarker for early diagnosis of AD. However, we would need to establish a standard
protocol for normalizing miRNA levels in plasma and CSF, prior to using miR-1273g-3p as
a biomarker for clinical diagnosis. Also, longitudinal observation should be conducted to
determine whether PSAD and/or PDAD patients progress to AD, as this could be a key to
accurately diagnose cognitively normal but Aβ-positive people as potential AD patients.
We used a pull-down assay to determine the function of miR-1273g-3p, and identified
1539 miR-1273g-3p-interacting transcripts with significant binding values in H4-APPswe
cells. GO analysis predicted that this gene set is primarily involved in mitochondrial
function. Among the 192 transcripts of mitochondrial genes found to interact with miR1273g-3p, we confirmed that functional interactions occurred with GLRX5, MTCH1 and
TIMM13 (Figure 5). In both H4-APPswe and SH-SY5Y cells, miR-1273g-3p expression had
the greatest decreasing effect on TIMM13, which is known to import and insert certain
proteins into the mitochondrial inner membrane, such as SLC25A12 and TIMM23 in complex with TIMM8 [45,46]. The mechanisms by which TIMM13 regulates mitochondrial
function have not been fully elucidated. However, it is known that the neurodegenerative disease, Mohr–Tranebjaerg syndrome, occurs due to a mutation in TIMM8A, which
acts as a complex with TIMM13, suggesting its association with neurodegenerative disease [47]. Knockdown of TIMM13 alone was associated with significant increases in JNK
activation, BACE1 expression, and Aβ production and TIMM13 expression tended to be
downregulated in the post-mortem AD brain. Overexpression of TIMM13 and inhibition of
miR-1273g-3p in miR-1273g-3p-transfected cells restored the increased BACE1 expression
and Aβ production to basal levels. These observations suggested that enhanced mitochondrial function could be helpful to prevent AD progression. This finding is supported by a
previous report that the upregulation of various mitochondrial genes responsible for the
mitochondrial stress response could rescue Aβ toxicity in AD model cell lines and AD
model animals, including mouse and C. elegans [48]. Among the genes that interact with
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miR-1273g-3p, genes with the GO terms “RNA binding”, “RNA splicing” and “poly(A)
RNA binding”, which show high significance, should not be overlooked to more fully
understand the function of miR-1273g-3p. RNA binding proteins are essential for the regulation of gene expression through various RNA processing pathways, such as alternative
polyadenylation (APA). In particular, the untranslated region (UTR)-APA has a definite
impact on the function of miRNAs [49]. Among the miR-1273g-3p-interacting genes associated with RNA processing, RPL23 is a ribosomal protein that is a component of the 60S
subunit, and PIN4 encodes a ribosomal RNA processing factor [50]. Negative regulation
of these genes could affect the stability of mRNAs encoded by other genes targeted by
miR-1273g-3p, indicating that the regulation of gene expression by miR-1273g-3p could
affect its self-regulation. We found that, although VDAC2 significantly interacted with
miR-1273g-3p, the expression of VDAC2 was unaffected by miR-1273g-3p overexpression.
This unexpected result may have been due to the change in expression of factors that
participate in RNA processing pathways, or to other regulatory factors. Although the
functions of these miR-1273g-3p-interacting genes were not fully elucidated in the present
study, we speculate that their changes may contribute to AD onset by triggering irreversible
mitochondrial dysfunction and consequent cell degeneration.
Accumulated evidences indicate that mitochondrial dysfunction might be a primary
factor in AD development [5,16,17]. Various factors have been proposed to induce mitochondrial dysfunction in AD progression. In particular, Aβ is reported to accumulate
and inhibit peptide turnover in mitochondria, activate mitochondrial fission proteins, and
eventually induce apoptosis [51–53]. In addition, defects in calcium signaling or neuroinflammation can impair mitochondrial function in AD [54,55]. However, the mechanism
impairing mitochondria in AD have not yet been clearly identified, and AD remains a
complex, multifactorial, and irreversible disease. Many recent studies have reported that
various miRNAs can regulate mitochondrial activities in AD. For example, miR-34a, which
is enhanced in brains of AD patients, targets mitochondrial genes (e.g., NDUFC2 and
UQCRB) to reduce ATP production and glycolytic capacity [56]. miR-195 is elevated in
hippocampus and targets mitofusin2, and its overexpression triggered the loss of mitochondrial membrane potential in the senescence-accelerated mouse-prone 8 mouse model [57].
Interestingly, miR-375, the level of which was increased in aMCI patients, as shown by our
microarray data, was also reported to regulate mitochondrial function. The expression of
miR-375 was increased in Aβ-treated SH-SY5Y cells and AD patients, and the inhibition of
its expression alleviated oxidative stress injury and the apoptosis of Aβ-treated SH-SY5Y
cells [58]. In addition, miR-375 promoted mitochondrial dependent apoptosis in patients
with Stevens-Johnson syndrome and toxic epidermal necrolysis [59] and reduced insulin
secretion in response to glucose and oxygen consumption related to glycolysis and pyruvate metabolism in rat and human islet cells [60]. Here, we report that miR-1273g-3p is
increased in AD, and that increased miR-1273g-3p induces mitochondrial dysfunction to
affect Aβ production. The previous and present findings therefore collectively suggest that
the accumulation of dysregulated miRNAs caused by various stimuli might negatively
affect homeostasis in brain and thereby cause irreversible brain degeneration.
A limitation of the present study is that the altered expression of miR-1273g-3p has
not been directly confirmed in brain tissues of AD patients. The level of miR-1273g-3p
has been reported to be increased in human umbilical vein endothelial cells (HUVECs)
stressed by acute glucose fluctuation [61] and in the LoVo colorectal cancer cell line [62].
miR-1273g-3p can also affect megakaryocyte differentiation by regulating cyclin and cyclin
dependent kinases [63]. Although analysis of the TissueAtlas database (https://ccb-web.
cs.uni-saarland.de/tissueatlas/, accessed 10 August 2021) predicted that miR-1273g-3p is
highly expressed in brain tissue, no experimental evidence to date has shown that miR1273g-3p is expressed in brain cells, and we were unable to identify the cells that express
and secrete miR-1273g-3p into the CSF and blood of AD patients. Nevertheless, this study
showed that in AD patients miR-1273g-3p is significantly increased in CSF, which is in
direct contact with brain parenchyma, as well as showing the functions of miR-1273g-3p in
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two types of brain cell line, H4-APPswe (neuroglioma) and SH-SY5Y (neuroblastoma) cells.
miRNAs can regulate gene expression not only in cells that express miRNAs but in other
cells by secretion and uptake [64]. These findings suggest that miR-1273g-3p could affect
various brain-derived cell types via paracrine or endocrine as well as autocrine effects.
In conclusion, we herein report that miR-1273g-3p is increased at an early stage
of AD, and that this AD-related upregulation of miR-1273g-3p induced mitochondrial
dysfunction by targeting various mitochondrial genes to facilitate Aβ production and
neurodegeneration. Thus, miR-1273g-3p might be a biomarker for early diagnosis of AD
and a potential therapeutic target for AD progression.
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